http://www.angletechnology.com/

research note, acrobat reader needed

latest results 24/1/06

LONDON (AFX) - Angle PLC said its venture company Provexis has successfully completed final phase trials of a nutraceutical which will be 'revolutionary' in controlling cardiovascular health.

Angle's venture company, Provexis, has received positive results for final human trials of an orange juice drink which contains a patented natural fruit extract called CardioFlow. CardioFlow has been developed by Provexis to benefit the circulation and reduce the risk of blood clots typically associated with heart attacks, stroke and deep vein thrombosis.

Provexis was founded by Angle in 2000 using its established Progeny process as a joint venture with the Rowett Institute. Angle retains a 32 pct holding in Provexis.

Angle said the final trial on the product, which started last October and concluded this week, showed that CardioFlow significantly altered the profile of blood platelets, making them less likely to initiate a thrombus.

The group expects the CardioFlow product to be integrated into a new branded beverage which will be on sale in the UK, with an approved health claim in early 2005.

more news today. somebody else seems to like the way angle do things and their success in bringing ideas to fruition.

ANGLE plc
('ANGLE' or the 'Company')

Award of Funding Contract from Carbon Trust

ANGLE is pleased to announce that it has been awarded a share of a 2.7m funding
contract from Carbon Trust, which is launching a Low Carbon Incubator Programme.
The Carbon Trust works with UK business and the public sector to cut carbon
emissions. Established by the Government to help the UK meet its climate change
obligations, the Carbon Trust creates practical, business-focused solutions to
carbon emission reductions.

Other participants in the programme are Imperial College Innovations, the wholly
owned technology transfer company of Imperial College London and LIFE-IC in
Sheffield who will both be working alongside ANGLE to bring early stage, low
carbon technologies to the market place. Participants will apply set entrance
and exit criteria to manage the number of qualifying start-up companies
receiving advisory support from the programme up to a maximum of 60,000 per
company.

The contract has a potential total maximum value of 900,000 for ANGLE. The
actual value will depend on the number of companies which ANGLE develops in its
consultancy and Progeny(R) process.

ANGLE will be focusing on the commercialisation of technology and the
development of technology-based industry, acting as a roaming advisor to the
Carbon Trust. ANGLE will be used to deliver specialist advice in business
development, company formation, capital formation, market research and
intellectual property rights.

The programme will support companies developing products based on technologies
such as novel materials, fuel cell and hydrogen-based travel.

Andrew Newland, Chief Executive of ANGLE, commented:

'I am delighted that ANGLE has been selected to participate in the Low Carbon
Incubator Programme following a rigorous selection process. Low carbon
technology is an expanding and innovative market, given the Government's drive
towards a low carbon economy and use of renewable energy.

Our involvement in this scheme will undoubtedly expose us to a number of
exciting opportunities in this area and is further acknowledgement of ANGLE's
successful venture management and consultancy model.'

bosley

You've been keeping this one to yourself! There seems to be lots positive that is going on. Any analyst forecasts?

Eric

hello eric. i had to sell agl to raise funds to buy more seo , but i still think this is a slow burn long termer. its also getting some serious attention in the press lately. i have seen a few small articles on agl and a half page featyre in the mail (i think) last week. as you say , lots of positives going on and certain investments almost ready to become products , eg cardioflow, which i like because of its obvious markets, airlines, health clubs, etc. i dont know where you would find any analysts forecasts so i cannot answer your question. as i no longer hold agl i dont follow the company as closely as i would if i was still a holder. wish i had had some funds when they bottomed.

bosley

Thanks for the help. Always a problem what to sell when you want to build up a stake in a company like SEO. I've partly solved the problem by turnind to CFDs which increases the exposire for your money. I've invested in a Hemscott report on AGL which gives a concensus EPS of 9.48p in 2005 and 18.2p in 2006. The latter would be a pe of about 8. Charts look positive so I think its worth a play.

Eric

eric, how long did it take to open a cfd account? who did you open one with and why?

this sounds very much like dgm and ibg. im not a holder any more , but still like the company.

ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce the launch of its latest
venture company, Customiser Group Ltd ('Customiser').



In accordance with ANGLE's Progeny(R) process for creating new ventures,
Customiser has secured intellectual property utilising psychological profiling
(more normally found in clinical psychology) and advanced pattern recognition.
The approach has been developed and patented by a team of leading academics
across a number of UK Universities. ANGLE expects to spend up to 500,000 in
this Progeny(R) venture.



Global spend on the internet is now well in excess of $100bn per year and
revenues from internet advertising now exceed $10bn per year. The market for
tailoring content to individual users is still in its infancy, but is already
generating several hundred million dollars per annum in revenue and is widely
predicted to grow rapidly.



Customiser's technology improves targeting of on-line advertising on internet
portal sites, relevancy of search results and product recommendations within
retail sites. The Customiser solution produces substantially better results
than rivals which rely simply on data such as demographics and internet browsing
behaviour.



It is expected that in the future, through Customiser's solution, internet users
will welcome personalised online adverts, search results and product
recommendations rather than wasting time with irrelevant information. Similarly
internet advertisers and retailers will target personally meaningful adverts and
product recommendations to receptive customers.



Commenting on the collaboration with ANGLE, the technology development team's
Andrew Fraser, said:



'We believe that internet personalisation will be worth several billion dollars
in the next few years and our collaboration with ANGLE will place us in an
outstanding position in this market.'

oh i wish i had more money


ANGLE plc

PROVEXIS ENTERS NEGOTIATIONS FOR A REVERSE TAKEOVER


ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce that venture company
Provexis Limited, the developer of natural bioactive ingredients has entered
negotiations to be acquired by AIM listed Nutrinnovator Holdings PLC
('Nutrinnovator') which develops and markets food and drink products.


The size of the proposed transaction is such that it will be defined as a
reverse takeover and accordingly will be subject, amongst other things, to the
approval of the Nutrinnovator shareholders. As an integral part of the proposed
transaction there will be a fund raising to raise up to 10 million for the
enlarged group. In the collective view of the Boards of Nutrinnovator and
Provexis, the required disclosure for the marketing campaign planned to achieve
the fundraising cannot be confined to a restricted group of potential investors.
As a result shares in Nutrinnovator have been suspended with immediate effect.
The expectation is that the proposed transaction, fundraising and associated
documentation will be agreed and announced on or around 24 March 2005.


Provexis Limited was founded by ANGLE in 2000 using its established Progeny(R)
process as a joint venture with the Rowett Institute (a leading human nutrition
research centre). ANGLE retains a 32% holding in Provexis, which is held on the
balance sheet at 300,000. ANGLE also holds a convertible loan note and certain
other debt instruments due from Provexis. The value of the transaction will be
confirmed following the marketing exercise and ANGLE will provide an update to
the market at that time.



Andrew Newland, Chief Executive of ANGLE, said;


'We are delighted to announce this major event for our venture company, Provexis
Limited. The combination of Provexis and Nutrinnovator presents a compelling
business platform comprising intellectual property, product development,
marketing and retail capability for exploitation of the 2.2bn global market for
heart healthy products and the substantially larger market for functional foods
generally. It is intended to build on Nutrinnovator's sales of its existing
Altu product line with the launch later in the year of Provexis' CardioFlow(R)
in the form of a cardiovascular health fruit drink. We believe this transaction
is a further demonstration of the strength of ANGLE's Progeny(R) process in
building value from intellectual property.

more good news from angle.

ANGLE plc

ANGLE Signs Three Year Management Contract with Qatar's Science & Technology
Park


ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce that it has been
appointed to manage Qatar's Science & Technology Park ('STP') until March 2009.

ANGLE will provide the Qatar Foundation, owner of the Science & Technology Park
in Doha, with a specialised project team, supported by additional staff
resources from Europe and the US. The team is charged with ensuring the
effective establishment and operation of the STP, which will be the emerging
international hub of research and commercialisation in the Middle East.

ANGLE will be responsible for leadership on strategic and operational
activities, management of technology transfer issues, the development of STP's
physical presence and external profile, as well as programs supporting Qatar's
development and commercialisation of technology. The value of the contract is
over 6 million over the 3 year term.

Qatar Foundation's Science & Technology Park aims to be an international
location for the development and commercialisation of technology. Part of the
one thousand hectare Education City campus in Doha, it is a place where
companies can develop their intellectual property and deliver it to the
marketplace; where research institutes undertake collaborative R&D; and where
entrepreneurs create and grow start-up technology companies.

STP will host companies from a range of sectors and sizes: multinational and
local companies, start-ups, training and consulting firms, and research
institutes. Multinational companies EADS, ExxonMobil, Microsoft, Shell and Total
have already announced their intention to establish operations at STP. They
join world-class Universities on the campus: Texas A&M University (engineering),
Carnegie Mellon (computer science and business), Weill Cornell (medicine) and
Virginia Commonwealth University (design).

His Excellency Dr Abdulla Al Kubaisi, Chairman of STP and member of the Qatar
Foundation Board of Directors, commented:

'Over the past fifteen months Qatar Foundation has been impressed with ANGLE's
performance to date in getting Qatar's Science & Technology Park off the ground.
We are very confident they will continue this success over the coming years.'

Andrew Newland, Chief Executive of ANGLE, said:

'I am delighted that ANGLE has been selected to deliver the next critical phase
of STP's development. This is an important milestone for our company, placing
us at the centre of one of the world's most ambitious technology
commercialisation projects. We will be leading the research and
commercialisation process in Qatar through a raft of STP programmes including
the creation and growth of new technology companies, establishment of a venture
capital fund, and development of an entrepreneurship training and mentoring
program. We are pleased to be working with such a high calibre Board of
Governors.'

write up in shares mag saying the reverse takeover of nutrinnovator by provexis will go ahead , subject to egm approval, on the 16th may and trading in provexis shares will commence on 20th may. one to watch.

more good news for agl.

ANGLE PLC

ESTABLISHMENT OF NEW US VENTURE


ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce the establishment of its
latest US-based venture, currently named ContraSoft. ANGLE has secured
intellectual property for ContraSoft in the field of computer software testing
developed by a team led by Dr. William Rogers.

Under the new agreement, ANGLE has an option to intellectual property (IP)
developed by Dr. Rogers. This IP offers the potential to change the approach
used worldwide for software testing, with substantial improvements in
productivity, reduced costs and improved software quality. The market for
software testing tools was over $1.0 billion in 2004 and is projected to grow at
9.3 per cent. per annum from 2003 to 2008 according to market research firm IDC.

In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE's
plan is to undertake the technology commercialisation and product launch
building value in ContraSoft.

Dr. Rogers has been active in many different aspects of the computer industry,
including software development, corporate management, research, and teaching.
Dr. Rogers was previously an Assistant Professor of Electrical and Computer
Engineering with the University of Texas. He has also taught courses for
businesses including IBM, Motorola, Hewlett Packard, Agilent and AMD. Dr.
Rogers has had previous commercial success, having owned and run a small company
and managed research and development for a small multinational software company.
He received his Master's and PhD from the University of Illinois at
Urbana-Champaign and his BSE from Tulane University.


ANGLE's Chief Executive Andrew Newland said:



'We are delighted to be working with Dr. Rogers to bring this exciting
technology to market. We believe the software testing market is a substantial,
fast growing market long over due for a new approach.'



Dr. William Rogers commented,



'The ANGLE model of combining management expertise and initial capital was very
attractive to me. I think it is a unique model and will accelerate the
development of the company.'

another wise investment from angle

For Immediate Release 6 May 2005

ANGLE plc

GEOMERICS: NEW VENTURE COMPANY

ANGLE plc ('ANGLE'), the venture management and consulting company specialising
in the commercialisation of technology, is pleased to announce the launch of its
latest venture company, Geomerics Ltd ('Geomerics').

Geomerics has secured intellectual property in the field of geometric algebra.
Geometric Algebra is a powerful new form of mathematics that vastly simplifies
complex geometric calculations. Geometric Algebra has its origins in the rather
esoteric academic discipline of theoretical cosmology, but it has now been
developed for application in a wide variety of disparate commercial applications
such as computer graphics in computer games and electromagnetic modelling which
is used, amongst other things, for optimising the design of mobile phone
antennas and reducing the radar signature of ships and planes.

One of the main differentiators between computer games is the speed and quality
of rendering of the graphics. With best-selling games generating several
hundred million dollars for their developers, the quest for better and faster
graphics engines is relentless. Geomerics' technology provides a step-change
improvement over the competition, and is set to revolutionise the market.
Overall the market for computer games is currently worth more than $30bn and
growing rapidly, and the market for graphics within these games is worth over
$600m per year.

Current electromagnetic modelling techniques do not give the accuracy required
in many applications, because the processing power required is prohibitive.
Geomerics' technology has already been used to resolve complex electromagnetic
modelling problems that rival systems have been unable to solve. The
electromagnetic modelling market is worth in excess of $100m per year and there
is also considerable latent demand.

This new approach in applying geometric algebra has been developed by a group of
four leading academics from the University of Cambridge: Professor Anthony
Lasenby (Professor of Astrophysics and Cosmology), Dr Mike Hobson (University
Reader in Astrophysics), Dr Chris Doran (EPSRC Advanced Research Fellow) and Dr
Joan Lasenby (Lecturer in Engineering). Geomerics has also engaged Professor
David Hestenes of Arizona State University (the original inventor of geometric
algebra) and Professor Alyn Rockwood of Colorado School of Mines (a geometric
algebra and computer graphics expert) in an advisory capacity.

In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE's
plan is to build a strong commercial offering in each of the key markets
sequentially, seeking a return on its investment in the medium term.
Simultaneously, development work will continue on the geometric algebra
platform. ANGLE expects to spend up to 500,000 in the Progeny(R) venture, which
is presently wholly owned by ANGLE.

Commenting on the collaboration with ANGLE, Professor Lasenby said:

'We have been developing the mathematics and technology behind Geomerics for a
number of years, and now is the perfect time to apply it to commercial
applications. We are delighted that ANGLE will be commercialising our
technology.'

ANGLE's Chief Executive Andrew Newland said:

'Computer graphics and electromagnetic modelling are large, growing markets.
Geomerics' technology is truly leading-edge and we believe it will revolutionise
a wide range of fields. We are delighted to be working with such a high calibre
of academic inventors.'

looks like things are happening.




ANGLE plc

PROVEXIS ANNOUNCES PROPOSED REVERSE TAKEOVER



ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce that venture company
Provexis Limited, the nutraceutical company which develops
scientifically-proven, proprietary, functional foods, supplements and medical
foods, has completed its negotiations with AIM listed Nutrinnovator Holdings PLC
('Nutrinnovator') which develops and markets specialist food and drink products.



The transaction, which is classified as a reverse takeover for Nutrinnovator, is
subject to the approval of the Nutrinnovator shareholders. Nutrinnovator has
received undertakings from shareholders holding approximately 76% of its current
issued share capital that they will vote in favour of the proposals.



In addition to the consideration shares to be issued to the shareholders in
Provexis, new shares in Nutrinnovator are being issued with a value at the
placing price of 5.9m comprising a 3.8m placing and the conversion of 2.1m of
loans. On completion, the new shares in Nutrinnovator are expected to be
re-admitted to trading on AIM on Thursday, 23 June 2005.



From completion, Nutrinnovator will be known as Provexis plc. The Chief
Executive of Provexis Limited, Dr Stephen Franklin, will become the Chief
Executive of Provexis plc. Dr Franklin has a BSc in Biology, a PhD in Applied
Biochemistry, an MBA and over ten years' experience in the creation and
development of early stage bioscience companies. He was previously a Principal
Executive with ANGLE. Dawson Buck, Deputy Chief Executive of ANGLE, will be
the Non-Executive Chairman of Provexis plc.



Dr Stephen Franklin, Chief Executive Officer of Provexis, commented: 'We are
delighted to announce the proposed reverse takeover of Nutrinnovator Holdings
plc. The rationale for integrating the two businesses is compelling with the
Enlarged Group combining a strong scientific team and impressive marketing and
sales expertise.



We believe that the Enlarged Group will be clearly differentiated in the
functional food industry in that it will develop innovative functional food
products with health benefits that are scientifically-proven and therefore have
the potential to carry credible health claims and endorsements. When one
combines this with proven speed-to-market credentials, we believe the result is
a company well positioned in the rapidly growing functional food market'.



Provexis was founded by ANGLE in 2000, using its established Progeny(R) process,
as a joint venture with the Rowett Institute (a leading human nutrition research
centre). Provexis' lead technology is CardioFlow which is a proprietary extract
of tomato, produced industrially to laboratory-determined specifications.
CardioFlow contains a range of tomato-derived components which inhibit platelet
aggregation a part of the blood-clotting process which can cause heart attack
and stroke. The first commercially available product containing CardioFlow will
be a fruit juice drink called Sirco. Nutrinnovator is in discussions with major
high-street retailers and multiple grocers to secure distribution channels for
Sirco and its aim is to launch it in two major UK retailers in the final quarter
of 2005.



ANGLE's investment cost held on the balance sheet to develop Provexis using the
Progeny(R) process is 0.46m. At the placing price, this original investment is
valued at 2.13m representing a multiple on investment of 4.6 times, an increase
of 1.67m over cost. The internal rate of return (IRR) on this investment if it
were to be realised at completion in cash at the placing price would be 78% per
annum.



In addition, ANGLE provided Provexis with convertible loan funding of 0.50m in
February 2005. It has been agreed that this loan will be uplifted to 0.83m and
converted into new shares in Provexis plc at the placing price, representing a
multiple on investment of 1.7 times and an increase of 0.33m over cost.



The overall gain to ANGLE from the transaction is 2.00m at the placing price.




ANGLE believes that the value of Provexis may increase substantially following
the placing if Provexis is successful in its launch of Sirco. ANGLE has
therefore agreed to invest 0.50m in the placing. After the placing and
completion of the reverse takeover, ANGLE will hold 24.8% of Provexis plc's
issued share capital.



ANGLE holds active investments in a total of 8 venture companies, which it has
developed using its established Progeny(R) process. This is the second
successful transaction for ANGLE's venture companies since ANGLE's flotation in
March 2004.





Andrew Newland, Chief Executive of ANGLE, said:



'We are delighted to have agreed this transaction in relation to our venture
company, Provexis Limited. The combination of Provexis and Nutrinnovator with
the new funding proposed presents a compelling business platform comprising
intellectual property, product development and marketing capability for
exploitation of the estimated 835m functional food market in the UK. We
believe this transaction is a further demonstration of the strength of ANGLE's
Progeny(R) process in building value from intellectual property.'

ANGLE plc

TRADING UPDATE



Further to the announcement today of the successful conclusion of negotiations
for Provexis' proposed reverse takeover of Nutrinnovator and funding for the
Enlarged Group, ANGLE plc, the venture management and consulting company
specialising in the commercialisation of technology, is pleased to provide an
update on trading and investment realisations for the year ended 30 April 2005.


Revenue for the year is expected to be not less than 4.0m, at least 39% up on
the previous year.


Operating profits on Consulting & Management are expected to be maintained at or
above the level for the previous year of 0.4m.


Execution of the strategy of investment in the establishment of new Progeny(R)
companies proceeded in line with expectations with planned expenditure to
establish and develop new ventures of some 2.0m being charged to the P&L. This
is a significant planned increase to the corresponding investment in the
previous year of 0.7m.


The overall gain to ANGLE from the Provexis transaction is 2.0m at the placing
price. Since the transaction was completed after the year end, it will fall in
the accounting year ended 30 April 2006 rather than in the year just ended as
had been planned. The internal rate of return (IRR) on ANGLE's investment if it
were to be realised at completion would be 78% per annum.


Following a fall in the share price of AIM-listed Corpora PLC since 31 October
2004, the value of ANGLE's shares in this company (taken as consideration for
the disposal of ANGLE's stake in Progeny(R) company, Exago Ltd) has declined,
resulting in the need for an increase in the provision for the diminution in
value of investments of 0.5m. Even after this write down, the investment is
still valued at 4.2 times cost and the IRR is 91% per annum.


Since its flotation, ANGLE has built its Progeny(R) pipeline of venture
opportunities under evaluation and established four additional Progeny(R)
companies, which the directors believe may have the potential for substantial
capital growth:

ContraSoft - computer software testing technology with the potential for
improvements in productivity, reduced costs and improved software quality;

Customiser - internet personalisation technology for the provision of
customised information to the user;

Geomerics - rapid computational technology for computer graphics and other
uses;

Novocellus - IVF technology for assessing embryo viability.


Progress has also been made in developing the Progeny(R) companies established
before ANGLE's flotation, notably:

Acolyte Biomedica has completed the development of its MRSA testing
product and has announced plans to launch the product commercially in the near
future;

NeuroTargets has progressed its nerve injury and pain treatments and
secured an alliance with BioFocus plc focused on discovering treatments for
nerve injury and pain;

Provexis, in addition to its reverse into Nutrinnovator and related
funding round, has progressed product development and clinical trials of Sirco,
its cardio-vascular health drink and has announced plans for the launch of the
drink in the final quarter of 2005.

Corpora PLC, the AIM listed company in which ANGLE holds shares following the
sale of its Progeny(R) company Exago to Corpora, has recently completed a 3m
placing to fund expansion and announced software product sales to Microsoft and
EDS.


All of the above Progeny(R) companies have been founded by ANGLE and developed
using ANGLE's Progeny(R) process to build value from intellectual property.



Andrew Newland, Chief Executive of ANGLE, said:


'I am pleased with ANGLE's progress in the execution of its ventures investment
strategy and in the development of its underlying Consulting and Management
business. We believe the Provexis transaction is a further demonstration of the
strength of ANGLE's Progeny(R) process in building value from intellectual
property

more good news today for angle.

For immediate release 31 May 2005


ANGLE plc

Acolyte Biomedica launches BacLite(R) Rapid MRSA test


ANGLE plc ('ANGLE') is pleased to announce that its venture company Acolyte
Biomedica Ltd ('Acolyte') has successfully launched its BacLite(R) Rapid MRSA '
superbug' test and that Salisbury District Hospital takes delivery of the first
system today.

The BacLite(R) system uses AK Rapid(R) technology developed by the Defence
Science and Technology Laboratories (Dstl), an agency of the Ministry of Defence
at Porton Down, Wiltshire.

Giving same day results, the BacLite(R) Rapid MRSA test will allow hospitals to
screen patients and hospital workers for the presence of the superbug. This
information will enable infection control teams to act quickly to prevent
hospital acquired infection.

In the UK, the combination of high bed occupancy and very infectious strains of
the superbug means that traditional screening methods are too slow for maximum
effect. Healthcare acquired infections, of which MRSA is the most significant,
are estimated to cause 5,000 deaths in the UK each year. By being able to act
quickly, hospitals can reduce significantly the incidence of mortality and
morbidity. In addition, MRSA costs the NHS around 1 billion per annum, so
reducing the incidence of the infection will have a major financial impact.

The final evaluation of the BacLite(R) system at three UK hospital laboratories,
including Salisbury District Hospital, showed the test can achieve in five hours
what current microbiological methods take two days to deliver. Conclusions to
studies illustrate the confidence that medical staff have when using BacLite(R)
Rapid MRSA test information for admitting patients; the probability that a
negative result was correct (negative predictive value) was over 99%.

Commenting on the launch, Dr Bill Mullen, CEO of Acolyte said:

'Identification of MRSA carriers is critical in overcoming the MRSA problem in
our hospitals. We expect this test to offer a rapid and cost effective screening
method at an important time in the fight against MRSA.'

Andrew Newland, CEO of ANGLE said:

'This launch is a significant milestone for Acolyte and underlines the high
value of the technology and the clinical importance of such a testing system. We
at ANGLE are proud to have played a pivotal role in leading the development of
Acolyte and, in so doing, bringing this vital diagnostic technology to market.

MRSA is just the first application of the technology, which in due course will
be applied to the diagnosis of a wide range of other serious infections.'

-ENDS-

more good news. i really don't understand the drop in price. being able to discover mrsa in 2 hours rather than 2 days has to be good for hospitals!!


Angle in research programme with Scottish National Blood Transfusion Service

LONDON (AFX) - Angle PLC said its venture company Acolyte Biomedica Ltd has entered into a joint research programme with the Scottish National Blood Transfusion Service ('SNBTS').

Angle said the programme is to establish the suitability of Acolyte's proprietary AK Rapid technology in the rapid and highly sensitive detection of bacterial contamination within blood platelets.

Under the agreement, both parties will collaborate and share resources in order to develop a version of Acolyte's BacLite diagnostic test system which has the potential to detect bacteria in platelets within 2-4 hours, thus dramatically improving the current testing time which can take several days.

on the 21 june 2005 Deutsche Bank AG and subsidiary companies purchase 100,000 shares taking their total to 10.35%. results for the year ended 30 April 2005 will be on Wednesday 6 July 2005. also,

ANGLE plc
('ANGLE' or the 'Company')

First day of Dealings for venture company Provexis plc on AIM

ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology, is pleased to announce that its venture company
Provexis plc, the nutraceutical company which develops scientifically-proven,
proprietary, functional foods, supplements and medical foods, announces
commencement of trading today in its ordinary shares on AIM under the ticker
symbol: PSX.L.

At the placing price of 5.6p per ordinary share, Provexis raised 5.9 million of
equity through an institutional placing of 3.8 million (before expenses) and
the conversion of 2.1 million of loans. On Admission and at the issue price the
market capitalisation was approximately 14 million. Following the Placing
ANGLE owns 24.8% of Provexis plc.

all in all , a good week for news.

results day.

Angle PLC
06 July 2005


For Immediate Release 6 July 2005




ANGLE plc
('ANGLE' or the 'Company')

Preliminary Results for the year ended 30 April 2005

ANGLE plc, the intellectual property and technology commercialisation company,
announces its preliminary results for the year ended 30 April 2005.

Financial Highlights

Turnover increased by 44% to 4.13 million (2004: 2.87 million).

Consulting and Management operating profit increased by 22% to 0.52 million
(2004: 0.43 million).

Investment to establish and develop new Ventures increased by 251% to
3.02 million (2004: 0.86 million) comprising Ventures operating
costs expensed in the profit and loss account of 1.79 million (2004: 0.68
million) and increase in fixed asset investments on the balance sheet of
1.24 million (2004: 0.19 million).

Loss before tax was 2.35 million. The loss is stated after new Ventures
development costs as above and a provision for diminution in value of
current asset investments of 1.57 million (2004: nil). In 2004 the
profit before tax was 2.33 million, which included profit of 2.31 million
on disposal of investments.

Basic loss per share of 13.87p (2004: profit 20.43p).

Cash at bank at year end 5.55 million (2004: 8.25 million).

Consulting and Management businesses entered new financial year with strong
sold order book of 8.98 million (2004: 3.23 million).


Operational Highlights

Consulting and Management won a major new Qatar Science & Technology Park
contract worth over 6m over 3 years.

Four new Progeny(R) companies formed: Contrasoft, Customiser, Geomerics and
Novocellus each offering the potential to address major worldwide markets in
software testing, internet personalisation, computer graphics and IVF embryo
viability respectively.

Good progress made by Progeny(R) companies: Acolyte Biomedica, NeuroTargets
and Provexis. In particular, Acolyte Biomedica has completed development of
its MRSA testing product and made first sales in May 2005. Provexis has
progressed product development and clinical trials of its cardio-vascular
health drink, Sirco, to be launched in Q4 2005.

Flotation of Provexis completed in June 2005 through a reverse acquisition
of Nutrinnovator Holdings, generating a gain in valuation for ANGLE of
2.00 million at the placing price.

New Directors of Ventures appointed in the UK and US and teams strengthened
with new recruits.

Negotiations in progress with major technology corporates, research
establishments and universities for commercialisation of their intellectual
property.



Hance Fullerton, Chairman, commented:

'ANGLE has made good progress in the growth of its business during the year.
The Consulting and Management businesses have delivered increased revenue and
profits and secured a major new contract in Qatar worth in excess of 6 million.

Our Ventures teams have expanded in the UK and US and relationships have been
further developed with leading technology organisations. Good progress has been
made in evaluating and developing new venture propositions. Work was completed
on the development of four new Progeny(R) companies during the year and the
existing Progeny(R) companies were developed against their milestones towards
realising value for our shareholders. Notably, the flotation of Provexis in
June 2005, generated a substantial gain in valuation for ANGLE once again
demonstrating the value of ANGLE's Progeny(R) process.'

Enquiries:
ANGLE plc 01483 295830
Andrew Newland, Chief Executive
Dawson Buck, Deputy Chief Executive
Ian Griffiths, Finance Director

Buchanan Communications 020 7466 5000
Richard Darby, Suzanne Brocks, James Strong


A presentation for analysts will take place today at 10:00am at the offices of
Buchanan Communications, 107 Cheapside, London, EC2V 6DN. Please call Buchanan
Communications for more details.

Notes to Editors

Founded in 1994, ANGLE is an international venture management and consulting
group focusing on the commercialisation of technology and the development of
technology-based industry. ANGLE creates, develops and advises technology
businesses on its own behalf and for its clients. ANGLE is listed on AIM
(AGL.L); further information can be found on
www.ANGLEplc.com




CHAIRMAN'S STATEMENT

Introduction

During the year ended 30 April 2005, ANGLE made good progress in developing its
business in accordance with plans set out at flotation in March 2004.

Strong growth of the Consulting and Management businesses was achieved and the
Ventures business was scaled up using the monies raised at the flotation.
Investments were made to establish three new Progeny(R) Companies in the year
with a fourth announced immediately after the year end.

Strong progress was made by Acolyte Biomedica, NeuroTargets and Provexis against
their milestones during the year, with a notable success being Provexis'
flotation completed in June 2005.

Results

In the year ended 30 April 2005, ANGLE increased turnover by 44% to 4.13
million (2004: 2.87 million). The loss before tax was 2.35 million, which was
principally made up of the following elements:

Increased profit before tax on the Consulting and Management businesses to
0.52 million (2004: 0.43 million), up by 22%;

Increased investment to establish and develop new Ventures expensed in the
profit and loss account of 1.79 million (2004: 0.68 million) up 164%;

A provision for diminution in the value of investments of 1.57 million
resulting from our holding in Corpora plc;

Interest of 0.24 million (2004: 0.05 million).

In 2004 the profit before tax was 2.33 million, which included profit of 2.31
million on disposal of Exago to Corpora plc. The basic loss per share was
13.87p (2004: profit 20.43p).

Finance

At the year end, ANGLE had cash at bank of 5.55 million (2004: 8.25 million).
The reduction was principally planned investment to establish and develop new
Ventures, which increased by 251% to 3.02 million (2004: 0.86 million)
comprising Ventures operating costs expensed in the profit and loss account of
1.79 million (2004: 0.68 million) and increase in fixed asset investments on
the balance sheet of 1.24 million (2004: 0.19 million).

In addition to cash balances, ANGLE held a quoted investment valued at 0.88
million at the year end relating to its holdings in Corpora plc. Subsequent to
the year end, completion of the Provexis flotation led to ANGLE holding an
additional quoted investment in Provexis plc valued at 3.47 million at the
placing price, which included a gain in valuation of 2.00 million.

Progeny(R) Companies

Significant progress has been made in expanding our Ventures capabilities and
activities. Senior staff have been appointed to lead and develop new Ventures
in both the UK and US markets, bringing experience from major corporate,
management consulting and venture capital roles.

During the year, we completed work on establishing four new Progeny(R)
Companies, three of which were founded in the year and the fourth immediately
thereafter. These companies address large markets in software testing, internet
personalisation, computer graphics and IVF embryo viability.

We are in negotiation with several major corporates and universities in the UK
and US to agree the basis for commercialisation of their intellectual property.

Of our four Progeny(R) companies existing at the start of the financial year,
three developed well during the year according to their agreed milestones. Of
particular note, was the work undertaken during the year towards the flotation
of Provexis, which completed in June 2005. Development of the fourth company,
IDR Therapeutics, was terminated when market evaluation indicated that there
were better alternative opportunities available to us.

Strategy and Outlook

ANGLE's objective is to achieve profitable long term capital growth for its
shareholders through the successful combination of its Consulting and Management
businesses with the establishment and development of a portfolio of Progeny(R)
Companies in a range of technology sectors. The Group's access to intellectual
property combined with its highly experienced management team puts it in a
strong position to fulfil this objective over the next few years.

The Consulting and Management order book remains strong at 8.98 million at 30
April 2005 (2004: 3.23 million), with particularly strong growth forecast in
the Middle East as a result of a major new contract in Qatar.

The outlook for the current financial year is encouraging. Since the start of
the financial year, we have already made a number of important announcements
including the:

flotation of Provexis through a reverse acquisition of Nutrinnovator
Holdings plc raising new equity of 5.9m from new funding and the
conversion of loans. Provexis' leading product Sirco, containing active
ingredient FruitFlow(R) (previously known as CardioFlow(R)) for
maintaining cardiovascular health, is scheduled to be launched in UK
supermarkets in the final quarter of 2005;

launch of the BacLite(R) MRSA detection product by Acolyte Biomedica
with sales to Barts and the London NHS Trust and Salisbury District
Hospital. The product has been well received and the company expects
strong demand. Separately Acolyte signed a joint venture with Scottish
National Blood Transfusion Service to develop a test for bacterial
contaminants in blood.

formation of a new Progeny(R) Company, Geomerics, to commercialise
intellectual property developed by academics from the University
of Cambridge for application in high speed computer games graphics.

The pipeline of potential Progeny(R) Companies is strong and presents
significant opportunities for ANGLE to further expand its Venture development
activities.

I would like to thank all members of the ANGLE team for their efforts in
delivering a strong performance in our first year as a public company. We have
an exceptional team, and I am grateful for all their hard work, enthusiasm and
commitment to the business. I look forward to working with them in the year
ahead.


Hance Fullerton
Chairman
5 July 2005



OPERATIONS SUMMARY

Consulting and Management

ANGLE has built profitable Consulting and Management businesses in the UK, US
and Middle East, generating revenue and providing expert in-house staff
capability as well as the opportunity to build important relationships with
corporates, government research establishments and universities. The
relationships with owners of intellectual property are a key channel for the
Group to identify and exploit opportunities to commercialise intellectual
property using its proprietary Progeny(R) process.

The Consulting and Management businesses have performed strongly during the
year. Fees increased 47% to 3.90 million (2004: 2.66 million) resulting in a
profit up 22% at 0.52 million (2004: 0.43 million). A number of major
contracts were secured during the year and the order book is strong at 8.98
million (2004: 3.23 million).

During the year, ANGLE secured its largest ever fee-for-service contract, to
manage the Qatar Science & Technology Park (QSTP) until March 2009. The
contract is worth over 6m in addition to the existing Qatar contracts. ANGLE
is responsible for the effective establishment and operation of the QSTP,
placing us at the centre of one of the world's most ambitious technology
commercialisation projects. We will be leading the research and
commercialisation process in Qatar through a raft of QSTP programmes including
the creation and growth of new technology companies, establishment of a venture
capital fund, and development of an entrepreneurship training and mentoring
program.

Ventures

The Ventures business made good progress during the year. The management teams
in the UK and US were both strengthened with new recruits, and, in accordance
with our plans set out at the time of flotation, investment to establish and
develop new Ventures was increased 251% to 3.02 million (2004: 0.86 million).
This comprised Ventures operating costs expensed in the profit and loss account
of 1.79 million (2004: 0.68 million) and an increase in fixed asset
investments on the balance sheet of 1.24 million (2004: 0.19 million).

The pipeline of new opportunities available to ANGLE has been significantly
developed. An example of this was the agreement with Ben Franklin Technology
Partners of Southeastern Pennsylvania (BFTP), an internationally recognised
economic development organisation, to advance the growth of technology-based
companies in the Greater Philadelphia region. It is contemplated that ANGLE
will commit $5 million over five years for funding new technology spin-outs that
meet its Progeny(R) requirements. This funding will be matched by BFTP on a
non-dilutive basis, thus doubling the leverage on ANGLE funds for creating
Progeny(R) companies.

The Greater Philadelphia region is home to many of the world's most renowned
academic institutions including the University of Pennsylvania - one of the
leading research universities in the United States. Collectively, the region's
academic institutions attract more than $1 billion of research funding per
annum, generating more than 200 patent applications per year. The region is
well recognised as a global leader in the bio-pharma and medical research arena.
ANGLE will serve as BFTP's preferred commercialisation partner for
technologies from universities, colleges and related institutions in the region.

This agreement demonstrates the benefit ANGLE obtains from the combination of
its Consulting and Management businesses with its Ventures business. ANGLE's
relationship with BFTP has developed from successful consulting work in
Pennsylvania, including the development of the strategy for nanotechnology in
the Commonwealth of Pennsylvania.

During the year, work was undertaken on establishing four new Progeny(R)
Companies:

ContraSoft: a software testing product company commercialising
technology developed by a corporate VP of R&D and University of
Texas academic to improve productivity, reduce costs and improve
quality in the software testing process.

Customiser: an internet personalisation company founded to
commercialise intellectual property generated by a Cambridge team of
psychologists and University pattern recognition experts to improve
on-line advertising and sales.

Geomerics: a computational graphics company founded just after the year
end to commercialise intellectual property developed by a team of
leading academics from the University of Cambridge, Colorado School of
Mines and Arizona State University for application in high speed
computer games graphics.

Novocellus: an IVF diagnostic company founded to commercialise
revolutionary technology from University of York for non-invasive
testing of the viability of IVF embryos.

Each of these new Progeny(R) Companies offer the potential to address major
worldwide markets with differentiated products protected by intellectual
property. The development of these companies is carefully controlled using
ANGLE's Progeny(R) process to minimise the development risk and enhance the
return to all the shareholders. Substantial capital returns are expected to
accrue to ANGLE shareholders from these new Progeny companies within three to
five years.

Good progress was made with ANGLE's existing Progeny(R) companies. Most
notably, work during the year resulted in the flotation on AIM of Provexis via a
reverse acquisition of Nutrinnovator Holdings plc raising 5.9 million through a
placing and the conversion of loans. Since the flotation was completed in June
2005, the financial impact of the transaction is not shown in ANGLE's accounts
to 30 April 2005.

Provexis was founded by ANGLE in 2000, using the Progeny(R) process, as a joint
venture with the Rowett Institute (a leading human nutrition research centre).
ANGLE's cost of investment on the balance sheet to develop Provexis using the
Progeny(R) process is 0.46 million. At the placing price, this original
investment is valued at 2.13 million representing a multiple on investment of
4.6 times, an increase of 1.67 million over cost. In addition, ANGLE provided
Provexis with convertible loan funding of 0.50 million in February 2005. This
loan has been converted into new shares in Provexis plc valued at 0.83 million
at the placing price, representing a multiple on investment of 1.7 times and an
increase of 0.33 million over cost. The overall gain in valuation to ANGLE
from the transaction is 2.00 million at the placing price.

ANGLE believes that the value of Provexis may increase substantially if Provexis
is successful in its launch of Sirco and has therefore invested 0.50 million in
the placing. Following the placing and completion of the reverse takeover,
ANGLE holds 24.8% of Provexis plc's issued share capital.

ANGLE currently holds investments in eight companies, which it has developed
using its established Progeny(R) process. Provexis is the second successful
transaction for ANGLE's venture companies since ANGLE's flotation in March 2004
and further demonstrates the value of ANGLE's Progeny(R) process.

In addition to work on Provexis' flotation, progress has also been made during
the year with the Progeny(R) companies established before ANGLE's flotation,
notably:

Acolyte Biomedica has completed the development of its MRSA testing
product and made its first sales of this product in May 2005.
Independent hospital analysis of the product has been highly favourable
and market demand looks promising;

NeuroTargets has progressed its nerve injury and pain treatments and
secured an alliance with BioFocus plc aimed at discovering treatments
for nerve injury and pain;

Provexis has progressed product development and clinical trials of
Sirco, its cardio-vascular health drink containing active ingredient
FruitFlow(R) (formerly known as CardioFlow(R)) and has announced plans
for the launch of the drink in the final quarter of 2005.

During the year, a detailed evaluation was undertaken of the market prospects
for Progeny(R) company, IDR Therapeutics. It was concluded that the market
dynamic for IDR's product offering had changed with the likely impact that the
company would require a significantly increased level of investment over a
longer timescale before a return would be achieved. Under these new
circumstances, the development of IDR Therapeutics no longer met our
requirements for investment under the Progeny(R) process. Accordingly the
programme was terminated. The cost of investment was 0.14 million, all of
which had previously been expensed through the profit and loss account.

Whilst it was disappointing to terminate the IDR programme, the strength of the
Progeny(R) process was demonstrated through identification of a potential
problem in advance of a major financial investment. Where problems are
identified in the future with other Progeny(R) companies, these will be
similarly terminated with the minimum investment from ANGLE having been
committed.

The share price of Corpora PLC, the AIM listed company in which ANGLE holds
shares following the sale of its Progeny(R) company Exago to Corpora, has
regrettably fallen significantly during the year resulting in the need for an
increase in the provision for the diminution in value of investments to 1.57
million. Even after this write down, ANGLE's original investment is still
valued at 0.85 million at the year end which is 4.0 times cost. On a more
positive note, Corpora has recently completed a 3m placing to fund expansion
and announced software product sales to Microsoft and EDS.

The Company's ongoing strategy is to create more Progeny(R) companies in the
biosciences, electronics, optronics, IT, materials, nanotechnology and software
sectors. At the year end, the pipeline for further Venture opportunities was
strong. ANGLE's business model, high calibre management and its Progeny(R)
process have been recognised by many potential technology partners as bridging a
critical gap in exploiting their intellectual property. As a result ANGLE is
evaluating new Venture opportunities with several of the UK's and US's top
technology universities, key research organisations and FTSE 100 / Fortune 500
businesses.

ANGLE's business is scaleable, well diversified into international markets and
benefits from a portfolio of companies specialising in a number of different
sectors. This diversity and flexibility is key to ANGLE's ongoing strength and
stability.

With a solid performance underpinning its activities, a strong sold order book
going forward and many exciting and profitable venture opportunities on the
horizon, ANGLE is facing the future with confidence and optimism.



ANGLE PLC
CONSOLIDATED PROFIT AND LOSS ACCOUNT
FOR THE YEAR ENDED 30 APRIL 2005

Note 2005 2004


Turnover
Consulting and Management 3,897,714 2,656,553
Ventures 234,437 219,257
4,132,151 2,875,810
Operating costs
Consulting and Management (3,375,944) (2,228,087)
Ventures (1,785,400) (674,918)
(5,161,344) (2,903,005)
Other operating income
Ventures
Profit on disposal of investments - 2,309,281

Operating profit / (loss)
Consulting and Management 521,770 428,466
Ventures
Operating loss (1,550,963) (455,661)
Profit on disposal of investments _______- 2,309,281
(1,550,963) 1,853,620

(1,029,193) 2,282,086
Provision for diminution in value of
current asset investments (1,566,372) -

Net interest 242,184 46,384
_________ _________
Profit / (loss) on ordinary activities
before taxation (2,353,381) 2,328,470

Tax on profit / (loss) on ordinary activities 3 37,850 (37,850)
_________ _________

Retained profit / (loss) for the year (2,315,531) 2,290,620
========== ==========
Earnings / (loss) per share 4
Basic (pence per share) (13.87) 20.43
Diluted (pence per share) (13.87) 19.45


The profit and loss account has been prepared on the basis that all operations
are continuing operations.



ANGLE PLC

CONSOLIDATED STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
FOR THE YEAR ENDED 30 APRIL 2005
2005 2004


Retained profit / (loss) for the year (2,315,531) 2,290,620

Currency translation differences (42,990) (26,647)
_________ _________
Total gains and losses recognised in the year (2,358,521) 2,263,973
========== ==========


ANGLE PLC

CONSOLIDATED BALANCE SHEET
AS AT 30 APRIL 2005
Note 2005 2004


Fixed assets
Tangible assets 52,742 31,959
Investments 1,755,779 516,782
_________ ________
1,808,521 548,741
Current assets
Investments 881,805 2,398,177
Debtors - due within one year 847,584 625,503
Debtors - due after one year 239,570 239,570
Cash at bank and in hand 5,548,638 8,246,871
_________ ________
7,517,597 11,510,121
Creditors: amount falling due
within one year (686,585) (1,063,116)
_________ ________
Net current assets 6,831,012 10,447,005
_________ ________
Total assets less current liabilities 8,639,533 10,995,746

Creditors: amounts falling due
after more than one year (1,316) (6,354)
_________ ________
Net assets 8,638,217 10,989,392
========== =========

Capital and reserves
Called up share capital 1,670,648 1,669,648
Share premium account 7,543,677 7,537,331
Profit and loss account (3,129,464) (770,943)
Other reserves 2,553,356 2,553,356
_________ ________
Shareholders' funds - equity interests 5 8,638,217 10,989,392
========== =========



ANGLE PLC

CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 APRIL 2005

2005 2004


Net cash inflow / (outflow) from operating activities (1,537,704) 48,592

Returns on investment and servicing of finance
Interest received 246,936 10,960
Interest paid (3,262) (7,307)
_______ _______
Net cash inflow from returns on investment
and servicing of finance 243,674 3,653

Capital expenditure and financial investment
Payments to acquire tangible fixed assets (49,177) (15,218)
Proceeds on disposal of tangible fixed assets - 650
Expenditure on investments (1,288,997) (106,317)
_______ _______
Net cash outflow for capital expenditure (1,338,174) (120,885)
and financial investment

Net cash outflow from acquisitions and disposals - -

Equity dividends paid - -
_______ _______
Net cash outflow before management
of liquid resources and financing (2,632,204) (68,640)


Financing
Net proceeds from issue of ordinary share capital (69,241) 8,269,775
Capital element of finance lease contracts (10,538) (20,212)
________ ________
Net cash inflow / (outflow) from financing (79,779) 8,249,563
_________ ________

Increase / (decrease) in cash in the year (2,711,983) 8,180,923
========== =========



ANGLE PLC

NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT
FOR THE YEAR ENDED 30 APRIL 2005

C1 Reconciliation of operating loss to net cash outflow from operating
activities

2005 2004


Operating profit / (loss) (1,029,193) 2,282,086
Depreciation of tangible fixed assets 27,244 30,823
Loss / (profit) on disposal of tangible fixed assets - 118
Exchange differences (42,664) -
Loss / (profit) on disposal of fixed assets investments - (2,398,177)
(Increase) / decrease in debtors (223,573) (332,361)
Increase / (decrease) in creditors within one year (269,518) 466,103
_________ ________
Net cash inflow / (outflow) from operating activities (1,537,704) 48,592
========== =========

C2 Analysis of net funds


1 May Cash flow 30 April
2004 2005


Net cash:
Cash at bank and in hand 8,246,871 (2,698,233) 5,548,638
Overdraft - (13,750) (13,750)
________ ________ ________
8,246,871 (2,711,983) 5,534,888

Debt:
Finance leases (16,891) 10,538 (6,353)
________ _________ _______
Net funds 8,229,980 (2,701,445) 5,528,535
========= ========= =========



C3 Reconciliation of net cash flow to movements in net funds

2005 2004


Increase / (decrease) in cash in the year (2,711,983) 8,180,923
Cash outflow from reduction in debt 10,538 20,212
New finance leases - (6,764)
Exchange differences - (26,647)
________ ________
Movement in net funds in the year (2,701,445) 8,167,724
Opening net funds 8,229,980 62,256
________ ________
Closing net funds 5,528,535 8,229,980
========= =========


ANGLE PLC

NOTES TO THE FINANCIAL INFORMATION
FOR THE YEAR ENDED 30 APRIL 2005

The financial information set out above does not constitute the Company's
statutory financial statements for the year ended 30 April 2005 within the
meaning of section 240 of the Companies Act 1985 but are derived from the
audited financial statements. The auditors have reported on these accounts and
their report was unqualified and did not contain statements under s237(2) or (3)
of the Companies Act 1985.

1 Basis of preparation

The financial information in this announcement has been prepared on the basis of
the accounting policies as set out in the financial statements for the year
ended 30 April 2004. The 2004 statutory accounts have been delivered to the
Registrar of Companies and the auditor's report on those accounts was
unqualified.

2 Compliance with accounting standards

The Financial Statements are prepared in accordance with the Companies
Act 1985 and applicable United Kingdom accounting standards.

The directors have, in accordance with sections 226 and 227 of the
Companies Act 1985, departed from the standard format of the profit and loss
account in presenting the financial statements. Profits and losses on disposals
of fixed asset investments, and provisions for diminution in value of fixed
asset investments are included in 'Other operating income' within operating
profit as these represent a return from a principal class of business activity.
Other material disposals that are not part of the main business activities are
shown below operating profit in accordance with the Companies Act 1985 and FRS3
- Reporting Financial Performance. Examples of such material disposals include
fixed assets, such as property, or current asset investments, such as listed
shares held for disposal in the short term.

3 Tax

The Group is eligible for and takes advantage of the substantial shareholdings
relief UK corporation tax exemption. This results in the gain from any
disposals of UK investments where the Group has an equity stake greater than
10%, and subject to certain other tests, being free of corporation tax.
Tax is therefore based on the net of profits in the Consulting and
Management businesses as relieved by losses incurred in the establishment and
development of new ventures.

4 Earnings per share

The basic and fully diluted earnings per share is calculated on an
after tax loss of 2.32 million (2004: profit 2.29 million).

The basic earnings per share is based on 16,697,500 weighted average
ordinary 10p shares (2004: 11,209,904). Share options are non-dilutive for the
year because of the loss. The fully diluted earnings per share is based on
16,697,500 weighted average ordinary 10p shares (2004: 11,775,197).

ANGLE PLC

NOTES TO THE FINANCIAL INFORMATION (Continued)
FOR THE YEAR ENDED 30 APRIL 2005

5 Reconciliation of movement in shareholders' funds


Group 2005 2004


Profit / (loss) for the year (2,315,531) 2,290,620
Conversion of warrants - 16,916
Gross proceeds from issue of shares 10,000 9,000,000
Issue expenses (2,654) (837,669)
Currency translation differences (42,990) (26,647)
_________ _________
Net addition / (reduction) to shareholders' funds (2,351,175) 10,443,220

Opening shareholders' funds 10,989,392 546,172
_________ _________
Closing shareholders' funds 8,638,217 10,989,392
========== =========

more business for agl.

For Immediate Release 20 July 2005

ANGLE plc

Wins Contract With The BioBusiness Alliance of Minnesota

ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology and the development of technology-based industry
is pleased to announce that its US Consulting and Management division has won a
contract with The BioBusiness Alliance of Minnesota, worth $200,000, to conduct
a comprehensive assessment of the state's biobusiness capabilities.

The BioBusiness Alliance of Minnesota is an industry-driven, business
development organisation of representatives from established and emerging
Minnesota companies, universities and government. It is devoted to building the
bioscience industry, retaining and creating jobs and economic growth, and
positioning Minnesota as a global leader in biobusiness. The Minnesota
biobusiness industry includes many World-class businesses and institutions such
Medtronic, 3M and the Mayo Clinic.

The information from the six month assessment, which will conclude in the fourth
quarter of 2005, will benchmark Minnesota against other countries and states.
The outcome of the process will identify the State's strengths and development
needs, and provide recommendations to target specific areas of biobusiness in
which Minnesota can compete as a global leader. These recommendations will
reflect the convergence of technologies, products, and markets that exist in the
State, and identify Minnesota's opportunity areas for growth.

ANGLE established a Minnesota office in August 2004 in recognition of the
significant business potential it believes exists in this State. ANGLE was
chosen following a rigorous national and international selection process. ANGLE
was selected for their significant experience both in conducting assessments in
the U.S. and internationally, and for their consulting expertise in the
technology industry.

Dr. Gary P. Evans, CEO of ANGLE's US Operations, said:

'We are delighted that ANGLE has been selected to deliver this innovative,
industry-driven assessment of Minnesota's biobusiness capabilities. We look
forward to working with the BioBusiness Alliance team to take the first step in
the long-term planning and development of a biobusiness strategy for Minnesota.'

Andrew Newland, Chief Executive of ANGLE plc, said:

'This contract is a great example of ANGLE's continuing expansion within the
United States. The Minnesota region is a prosperous biobusiness arena and this
contract will position ANGLE alongside some of the biggest names in the market.
We expect that Minnesota will emerge as a further key platform for our Ventures
business in the US.'

re organization taking place.

1 August 2005

ANGLE plc

('ANGLE' or the 'Company')

Formation of Executive Management Board and Board Change

ANGLE plc, the venture management and consulting company specialising in the
commercialisation of technology and the development of technology-based industry
announces the formation of an Executive Management Board which will report
directly to the ANGLE plc Board.

In recognition of the Company's recent successes, rapid expansion and future
prospects across the United Kingdom, United States and the Middle East, ANGLE
has strengthened its management structure and promoted Stephen Bates, currently
Director of UK Ventures, to UK Chief Executive. Responsibility for HR,
marketing, IT and operations will now be devolved from the Board to regional
chief executives ensuring full responsibility for all activities in their
respective regions.

With immediate effect, the Executive Management Board will consist of Group CEO,
Andrew Newland and Finance Director, Ian Griffiths, together with:

Stephen Bates, UK Chief Executive

Stephen Bates has an MA in engineering, and an MBA. Following 10 years within
the product development industry his career has taken him to Scientific
Generics, Arthur D. Little and Marks & Spencer prior to joining ANGLE in 2004.
Dr Gary Evans, US Chief Executive

Gary Evans has a BSc in Chemistry, a PhD in Physical Chemistry, and a Diploma in
Management Science and was Visiting Professor in Innovation Management at the
Robert Gordon University, Aberdeen. Following a career with Cambridge Life
Sciences and then Scottish Enterprise, Dr. Evans joined ANGLE in 1997.

Dr Eulian Roberts, Middle East Chief Executive

Eulian Roberts has a BSc in Microbiology, a PhD in Molecular Biology and an MBA.
He gained three years' post-doctoral experience and then joined Scottish
Enterprise. He then became chief executive of the Stirling University Innovation
Park, managing director of Coventry University Enterprises Limited and a
director of the UK Science Park Association. Dr Roberts joined ANGLE in 1998.

As a result of these changes, Dawson Buck will be stepping down from his
position as Deputy Chief Executive, with immediate effect. He remains a director
of ANGLE's venture companies, Corpora plc and Provexis plc.

Commenting on the new organisational structure, Group CEO, Andrew Newland, said:

'The formation of an Executive Management Board establishes a clear management
structure and accountability by region which will improve the efficiency and
integration of our Consulting & Management and Ventures operations, streamline
overheads and facilitate our continuing rapid growth.

The new management structure gives us the platform we need to grow the business
substantially. I am delighted to have such high calibre individuals within the
Executive Management Board.

I would also like to put on record my thanks to Dawson Buck for all his
contributions to the ANGLE Board over the last five years.'